PubMed
Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract (review)
Sikiric P, Seiwerth S, Rucman R, et al. Curr Pharm Des. 2018
Compare
Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.
Last reviewed . By the PeptIQ team.
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 97% · Mixed 3% · Unfavorable overall 0%
Benefits users selected when logging a favorable or mixed check-in.
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Median bucket: 0.6–1 mg · Most common: 1–2 mg
Reports span 0.2–2 mg
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Among repeat reporters, 90% said they felt similar to their last entry, 10% more positive, and 0% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 215 days · Based on 20 repeat reporters
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 3% · Mixed 97% · Unfavorable overall 0%
Benefits users selected when logging a favorable or mixed check-in.
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Median bucket: 2–3 mg · Most common: 2–3 mg
Reports span 0 to ≥ 5 mg (open-ended top bucket)
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Among repeat reporters, 89% said they felt similar to their last entry, 11% more positive, and 0% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 46 days · Based on 45 repeat reporters
Published sources linked on the BPC-157 (Oral) and GHK-Cu wiki pages.
PubMed
Sikiric P, Seiwerth S, Rucman R, et al. Curr Pharm Des. 2018
PubMed
Sikiric P, Seiwerth S, Rucman R, et al. Curr Pharm Des. 2018
PubMed
Ilic S, Drmic D, Franjic S, et al. Life sciences. 2011
PubMed
Tlak Gajger I, Ribarić J, Smodiš Škerl M, et al. Journal of veterinary pharmacology and therapeutics. 2018
Review Article
Pickart L, Margolina A. Cosmetics. 2018
PubMed
Pickart L. J Biomater Sci Polym Ed. 2008
PubMed
Pickart L, Margolina A. Biomed Res Int. 2014
ClinicalTrials.gov
ClinicalTrials.gov. Clinical trial registry. 2024
PubMed
Pickart L, Vasquez-Soltero JM, Margolina A. BioMed research international. 2015
PubMed
Yang X, Zhang Y, Huang C, et al. Macromolecular bioscience. 2022